Hill-Rom (NYSE:HRC) issued an update on its first quarter earnings guidance on Tuesday morning. The company provided EPS guidance of $0.77-0.79 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.79. The company issued revenue guidance of $670 million, compared to the consensus revenue estimate of $656.42 million.

Shares of Hill-Rom (NYSE:HRC) opened at $88.34 on Wednesday. Hill-Rom has a 12 month low of $55.04 and a 12 month high of $88.91. The firm has a market cap of $5,810.00, a PE ratio of 44.39, a PEG ratio of 1.65 and a beta of 1.19. The company has a current ratio of 1.77, a quick ratio of 1.34 and a debt-to-equity ratio of 1.55.

Hill-Rom (NYSE:HRC) last announced its earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.05. Hill-Rom had a net margin of 9.36% and a return on equity of 21.07%. The business had revenue of $738.30 million during the quarter, compared to the consensus estimate of $731.10 million. During the same quarter in the prior year, the firm earned $1.18 earnings per share. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. research analysts expect that Hill-Rom will post 4.32 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, December 29th. Stockholders of record on Friday, December 15th were paid a dividend of $0.18 per share. The ex-dividend date was Thursday, December 14th. This represents a $0.72 annualized dividend and a dividend yield of 0.82%. Hill-Rom’s dividend payout ratio (DPR) is 36.18%.

A number of brokerages recently commented on HRC. Zacks Investment Research upgraded shares of Hill-Rom from a sell rating to a hold rating in a research report on Monday, September 18th. KeyCorp restated a buy rating and issued a $82.00 price objective on shares of Hill-Rom in a research report on Tuesday, October 17th. ValuEngine downgraded shares of Hill-Rom from a buy rating to a hold rating in a research report on Saturday, November 4th. Needham & Company LLC reduced their price objective on shares of Hill-Rom from $93.00 to $90.00 and set a buy rating for the company in a research report on Monday, November 6th. Finally, Stifel Nicolaus increased their target price on shares of Hill-Rom from $84.00 to $85.00 and gave the company a buy rating in a report on Monday, November 6th. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Hill-Rom presently has an average rating of Hold and an average target price of $91.75.

In other news, CEO John J. Greisch sold 125,241 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $82.59, for a total transaction of $10,343,654.19. Following the completion of the transaction, the chief executive officer now directly owns 280,851 shares of the company’s stock, valued at approximately $23,195,484.09. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Paul Sherwood Johnson sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $82.99, for a total transaction of $82,990.00. Following the transaction, the senior vice president now directly owns 1,066 shares of the company’s stock, valued at $88,467.34. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 226,241 shares of company stock valued at $18,708,644. 2.20% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “Hill-Rom (HRC) Issues Q1 Earnings Guidance” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/hill-rom-hrc-issues-q1-earnings-guidance/1801172.html.

About Hill-Rom

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Earnings History and Estimates for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.